Biotechnology news

More than 8,500 individuals from the field of pharmaceutical research are expected to attend this year's AAPS Annual Meeting and Exposition November 8 - 12, 2009 at the Los Angeles Convention Center in California. During the meeting, scientists from around the world will have the opportunity to present new research, methods and technologies as they relate to the field of pharmaceutical sciences.

JHP Pharmaceuticals, LLC ("JHP") announced that it had developed, and received approval by the FDA for Dantrium® IV (dantrolene sodium for injection), a rapidly mixing product. Dantrium® IV now reconstitutes in approximately 20 seconds, which is 4 times faster than before, saving valuable time and effort during a malignant hyperthermia (MH) emergency.

JHP Pharmaceuticals, LLC ("JHP") announced that it had developed, and received approval by the FDA for Dantrium® IV (dantrolene sodium for injection), a rapidly mixing product. Dantrium® IV now reconstitutes in approximately 20 seconds, which is 4 times faster than before, saving valuable time and effort during a malignant hyperthermia (MH) emergency.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it is initiating a Phase 2 study of BCX4208 for the treatment of gout. The primary objective of BioCryst's Phase 2 study is to determine the effect of different doses of orally administered BCX4208 on serum uric acid levels in patients with gout. The gout trial is expected to enroll up to 120 subjects.

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that it has begun enrolling patients in a Phase 1 study of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase (TS) inhibitor, as a potential treatment for advanced solid tumors. This open-label, dose-finding study will evaluate the safety and pharmacokinetics of ONX 0801 in patients with advanced solid tumors.

The Senate Finance Committee on Thursday defeated an amendment that sought to squeeze more money out of pharmaceutical companies to help pay for the costs of changing the health care system. The panel's vote was a victory for President Obama and Finance Chairman Max Baucus.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA's Orange Book for Eli Lilly's Evista® (raloxifene hydrochloride) Tablets in litigation concerning Teva's abbreviated new drug application to market a generic version.

Latest Pharma Industry / Biotech Industry News From Medical News Today.